Vanguard Global Advisers’s ClearPoint Neuro CLPT Stock Holding History

Vanguard Global Advisers’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$181K	Hold	10,140	–	–	﹤0.01%	2539
2026 Q1	$92.3K	Buy	+10,140	New	+$128K	﹤0.01%	2759

Other funds holding CLPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

CFM

Compass Financial Management Tampa, Florida $829M AUM

Vanguard Global Advisers's CLPT Position: Q2 2026 in Review

Vanguard Global Advisers held its ClearPoint Neuro (CLPT) position steady in Q2 2026 at 10,140 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #2539.

Vanguard Global Advisers first reported a position in CLPT in Q1 2026 and has held it in 2 quarters since. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

Vanguard Global Advisers held 10,140 shares of ClearPoint Neuro worth $181K as of Q2 2026.
Vanguard Global Advisers left its ClearPoint Neuro share count unchanged in Q2 2026.
ClearPoint Neuro made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2539 holding.
Vanguard Global Advisers first reported a position in ClearPoint Neuro in Q1 2026 and has held it in 2 quarters since.
129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.